Drug Profile


Alternative Names: Incivek; Incivo; LY-570310; MP-424; Telavic; VX-950

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Vertex Pharmaceuticals
  • Developer Janssen R&D Ireland; Mitsubishi Tanabe Pharma Corporation; Vertex Pharmaceuticals
  • Class Antivirals; Cyclohexanes; Cyclopentanes; Cyclopropanes; Peptidomimetics; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 03 Aug 2017 No recent reports on development identified - Registered for Hepatitis C in Taiwan (PO)
  • 01 Aug 2017 Discontinued - Phase-I/II for Hepatitis C (Combination therapy, In adolescents, In children) in USA, Italy, Spain, Belgium, Germany and United Kingdom (PO), because not listed on Vertex and Janssen Pharmaceutica pipeline, August 2017
  • 07 Jun 2016 Vertex terminates a phase I/II trial in Hepatitis C (Combination therapy, In adolescents, In children) in USA, United Kingdom, Belgium, Germany, Italy and Spain (NCT01701063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top